Next Article in Journal
Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond
Previous Article in Journal
Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease

by 1,2, 1,2 and 1,2,*
1
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1Z5, Canada
2
Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON M5G 1Z5, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s3), 165-172; https://doi.org/10.3747/co.27.7159
Received: 7 August 2020 / Revised: 8 September 2020 / Accepted: 9 October 2020 / Published: 1 November 2020
The results of the SHARP trial established sorafenib, a tyrosine kinase inhibitor (TKI), as the sole first-line treatment option in advanced hepatocellular carcinoma (HCC) for more than a decade. In 2020, there has been a surge in new therapies for HCC, including immunotherapeutic strategies and the approval of a number of novel TKIs. In addition to sorafenib, lenvatinib and combination atezolizumab–bevacizumab now represent standard first-line treatment options. As those systemic therapy options begin to be better utilized, assurance of adequate liver function and optimal timing are required to improve patient outcomes. Furthermore, sequencing of the agents will have to be carefully tailored, given the increasing armamentarium of choices. Here, we discuss the role of lenvatinib and sorafenib in the first-line management of HCC.
Keywords: hepatocellular carcinoma; immunotherapy; checkpoint inhibitors; nivolumab; pembrolizumab; atezolizumab; lenvatinib; sorafenib; systemic therapy; tyrosine kinase inhibitors hepatocellular carcinoma; immunotherapy; checkpoint inhibitors; nivolumab; pembrolizumab; atezolizumab; lenvatinib; sorafenib; systemic therapy; tyrosine kinase inhibitors
MDPI and ACS Style

Perera, S.; Kelly, D.; O’Kane, G.M. Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease. Curr. Oncol. 2020, 27, 165-172. https://doi.org/10.3747/co.27.7159

AMA Style

Perera S, Kelly D, O’Kane GM. Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease. Current Oncology. 2020; 27(s3):165-172. https://doi.org/10.3747/co.27.7159

Chicago/Turabian Style

Perera, S., D. Kelly, and G. M. O’Kane. 2020. "Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease" Current Oncology 27, no. s3: 165-172. https://doi.org/10.3747/co.27.7159

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop